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Abstract
There is association between exposure to estrogens and the development and progression of hormone-dependent
gynecological cancers. Chemical carcinogenesis by catechol estrogens derived from oxidative metabolism is thought to
contribute to breast cancer, yet exact mechanisms remain elusive. Malignant transformation was studied in MCF-10A
human mammary epithelial cells, since estrogens are not proliferative in this cell line. The human and equine estrogen
components of estrogen replacement therapy (ERT) and their catechol metabolites were studied, along with the influence
of co-administration of selective estrogen receptor modulators (SERMs), raloxifene and desmethyl-arzoxifene (DMA), and
histone deacetylase inhibitors. Transformation was induced by human estrogens, and selectively by the 4-OH catechol
metabolite, and to a lesser extent by an equine estrogen metabolite. The observed estrogen-induced upregulation of
CYP450 1B1 in estrogen receptor negative MCF-10A cells, was compatible with a causal role for 4-OH catechol estrogens, as
was attenuated transformation by CYP450 inhibitors. Estrogen-induced malignant transformation was blocked by SERMs
correlating with a reduction in formation of nucleobase catechol estrogen (NCE) adducts and formation of 8-oxo-dG. NCE
adducts can be formed consequent to DNA abasic site formation, but NCE adducts were also observed on incubation of
estrogen quinones with free nucleotides. These results suggest that NCE adducts may be a biomarker for cellular
electrophilic stress, which together with 8-oxo-dG as a biomarker of oxidative stress correlate with malignant transformation
induced by estrogen oxidative metabolites. The observed attenuation of transformation by SERMs correlated with these
biomarkers and may also be of clinical significance in breast cancer chemoprevention.
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Introduction
With an average lifetime risk of 8–10%, breast cancer is the
most common malignancy in women in the Western world.
Longer exposure to estrogens predisposes women to develop
hormone-dependent gynecological malignancies. A central role for
circulating hormones in breast cancer development is further
supported by the marked reduction in cancer incidence after
surgical or chemical ovariectomy. Direct action of estrogen has
been shown to cause malignant transformation of normal breast
epithelial cells in culture, even when these cells are unresponsive to
classical estrogen receptor (ER) mediated proliferation [1].
Malignant phenotypes of the breast arise as a result of a series of
mutations, most likely in genes associated with tumor suppressor,
oncogene, DNA repair, or endocrine function. Chemical carcino-
genesis resulting from estrogen oxidative metabolism to quinoid
metabolites is associated with electrophilic and oxidative damage
to DNA. Typical DNA damage includes formation of stable
adducts, nucleobase oxidation, formation of abasic sites, single
strands breaks, mutations such as GRT transversions, loss of
heterozygosity, and epigenetic changes.
Formation of the catechol estrogens, 2-OHE and 4-OHE, is
catalyzed by the action of CYP450 enzymes, most importantly
CYP450 1B1-mediated formation of the genotoxic 4-OHE
(Figure 1). DNA modification by the carcinogenic 4-OHE quinone
is known to cause depurination leading to abasic sites and
nucleobase catechol estrogen (NCE) adducts. In contrast, DNA
adducts formed by 2-OHE quinone are proposed to be chemically
stable, not generating appreciable amounts of abasic sites [2].
Together with receptor-mediated, or hormonal carcinogenesis, by
estrogen and estrogen metabolites, the genotoxic o-quinone
metabolites of estradiol (E2) and estrone (E1) are argued to be
initiators and promoters of breast cancer via chemical carcino-
genesis (Figure 1).
Estrogen replacement therapy (ERT) remains a cornerstone of
contemporary women’s healthcare, despite outcomes from the
Women’s Health Initiative clinical trials that reported the elevated
risks of breast and lung cancer associated with ERT [3,4,5]. These
trials also confirmed the benefits of ERT including reductions in
osteoporotic fractures, and adverse postmenopausal symptoms,
highlighting the need for new ERT agents with minimized cancer
risk. Selective estrogen receptor modulators (SERMs), such as the
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potential to fill such a need [6]. An ideal SERM would provide
estrogenic agonist activity in bone, the cardiovascular system, and
the central nervous system, whilst exerting antagonist activity in
the breast and uterus [7,8,9,10]. It was therefore of interest to
study malignant transformation of human mammary epithelial
cells induced by the components of ERT and modulated by
benzothiophene SERMs. Since the actions of histone deacetylase
(HDAC) and SERMs has been linked and HDACs are in clinical
trials for breast cancer [11,12], HDAC inhibitors (HDACIs) were
also of interest.
The non-tumorigenic MCF-10 cell line has the morphological
characteristics of normal breast epithelial cells [13,14,15]; in
response to extended treatment with E2, anchorage-independent
growth was induced, a phenotype of malignant transformation,
strongly correlated with tumorigenicity [16,17]. CYP450 1B1 was
implicated since protein expression was upregulated by estrogen
treatment. The objectives of this work were: firstly to study
malignant transformation of a mammary cell line, modeling
estrogen-induced chemical carcinogenesis resulting from ERT and
to examine the influence of SERM and HDACI co-administra-
tion; and, secondly to examine the correlation of malignant
transformation with biomarkers of cellular electrophilic and
oxidative stress. The biomarkers investigated, NCE adducts and
8-oxo-dG, were elevated by estrogens and attenuated by SERM
co-treatment.
Results
Malignant transformation of MCF-10A cells induced by
estrogens and metabolites
Treatment of MCF-10A immortalized, human breast epithelial
cell cultures with E2 or the catechol metabolite 4-OHE2, for four
weeks, led to significantly increased cellular transformation as
Figure 1. Estrogens (E1 and E2) undergo oxidative metabolism to C2 and C4 catechols. Catechols are further oxidized to form o-quinones.
Based on t1/2 and reactivity, the most mutagenic species is 4-OHE1/2 and its further oxidized species. 4-OHE-3,4-o-quinone (shown in red) can redox
cycle to form ROS, oxidize DNA (measured as 8-oxo-dG), alkylate DNA (form abasic sites, and stable adducts), and chemically modify other important
macromolecules such as dNTP, GSH, and cellular proteins.
doi:10.1371/journal.pone.0027876.g001
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soft-agar for a further four week-period (Figure 2A). The COMT
(catechol O-methyl transferase) inhibitor, Ro 41-0960, would be
expected to block methylation and deactivation of the catechol
estrogen (Figure 1) and to increase the extent of cellular
transformation, however, the observed increase, when the
inhibitor was co-administered with 4-OHE2 did not reach
significance compared to 4-OHE2 alone. In a similar way, cells
were treated with equilenin (EN), and its oxidative metabolite
formed on CYP450 1B1 action, 4-OHEN (4-hydroxyequilenin).
Co-treatment of 4-OHEN with COMT inhibitor, proved to be
cytotoxic to MCF-10A cells over the 4-week treatment period,
therefore, in the case of the equine estrogens, the product of
COMT mediated methylation, 4-MeOEN (4-methoxyequilenin),
was studied. 4-OHEN caused significant cellular transformation
compared to vehicle control, whereas EN and 4-MeOEN did not
reach significance. The equine estrogens were less potent inducers
of cellular transformation than human estrogens as measured by
anchorage-independent colony growth.
The observation of greatest transformation induced by the 4-
OH-catechol estrogen metabolites is compatible with a causal role
for CYP450 1B1 in mediating cellular transformation, therefore,
mRNA and protein levels for this enzyme were measured in
response to treatment with E2. CYP450 1B1 was upregulated in
response to E2 as demonstrated by mRNA (Figure 3A) and protein
levels over the one week course of E2 treatment (Figure 3B).
CYP450 1A1 and 1B1 catalyze estrogen oxidative hydroxylation
at the C2 and C4 positions, respectively, therefore, transformation
of MCF-10A cells was studied after extended treatment with 2-
OHE1 or 4-OHE1, and for comparison, the parent estrogen, in
this case E1 (Figure 1B). Treatment with 2-OHE1 did not
significantly induce transformation, moreover, co-treatment of
cells with E1 and the CYP450 inhibitor, a-naphthoflavone (aNF),
a non-competitive CYP450 1B1 inhibitor (Ki=2.860.5 nM),
completely ablated cellular transformation. Although a-NF
inhibits other CYP450 isoforms, the simplest conclusion is that
inhibition of CYP450 1B1-mediated oxidation of estrogens to the
4-OH catechols and their o-quinones by a-NF blocks transforma-
tion by preventing formation of these oxidative metabolites.
Inhibition of MCF-10A cell transformation: Effects of
benzothiophene SERMs and HDAC inhibitors
Raloxifene is clinically indicated for chemoprevention of
invasive breast cancer and arzoxifene delivered similar efficacy
in clinical trials [18]. Evidence for ER-independent mechanisms
that may contribute to chemoprevention by benzothiophene
SERMs has been reported by ourselves and others [19,20].
HDAC inhibition has been reported to synergize actions of
SERMs in breast cancer cells and HDACIs are in clinical trials
[12,21,22]. Co-treatment of MCF-10A cells with the HDACIs,
SAHA or TSA, did not attenuate estrogen-induced cellular
transformation (Figure S1), therefore combinations were not
explored. However, both benzothiophene SERMs, DMA and
raloxifene significantly attenuated estrogen-induced cellular trans-
formation, ablating the effects of estrogen (Figure 4A, 4B).
Purine NCE adduct formation
A preliminary experiment was performed to detect purine NCE
adducts in the media from MCF-10A cells at the end of the fourth
week of treatment with E2 or 4-OHE2, the latter with or without
COMT inhibitor (Figure 5). Media was subjected to solid phase
extraction before assay by LC-MS/MS, in which MRM (multiple
reaction monitoring) analysis of the appropriate mass transition
(parent ion m/z and fragmentation to the appropriate purine m/z)
was used to indicate the presence of the appropriate NCE adduct.
N3-Me-guanine and N7-Me-guanine were used as internal
standards for relative quantitation. This preliminary analysis
demonstrated the presence of 4-OHE1-Gua, and 4-OHE2-Gua
adducts, and adducts were not detected in vehicle treated media.
To further explore the apparent correlation between NCE
adduct formation and cellular transformation, 4-OHE-1-N7Gua
was synthesized and characterized spectroscopically. The
15N
Figure 2. Malignant transformation induced by endogenous
and equine estrogens: MCF-10A cellular transformation in-
duced by estrogens and metabolites was measured as
anchorage-independent growth in soft agar after four weeks.
A. Cells were treated with estrogens or metabolites (1 mM) and COMT
inhibitor Ro 41-0960 (Ro, 3 mmol) for 4 weeks before transfer to soft
agar. Using one-way ANOVA with Dunnett’s post test: *** p,0.001;
** p,0.01 versus DMSO control. B. MCF-10A cellular transformation
induced by E1 with or without the CYP450 1B1 inhibitor aNF (3 mM),
and a comparison between transformation potency of 2-OHE1 versus 4-
OHE1 in MCF-10A cells, 1 mM each. Using one-way ANOVA with
Dunnett’s post test: *** p,0.001; ** p,0.01 versus DMSO control.
doi:10.1371/journal.pone.0027876.g002
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labeled NCE standard. Tandem MS parameters were optimized
for positive MRM mode detection of Gua-NCE adducts (mass
transitions m/z 438R152 and 436R152). The solid phase
extraction of culture media was calculated to proceed with 70%
efficiency using spiked media. Addition of
15N-labeled standards to
media before extraction ensured accurate quantitation of NCE
adducts. NCE adducts can themselves be oxidized to o-quinone
and 8-oxo-dG adducts, therefore stability was studied over 27 h at
3,pH,10 using synthetic standards, optimal stability being
observed at pH,6.5 (Figure S2). At physiological pH in phosphate
buffer, adenine NCE adduct degradation was about 80% complete
after 27 h, while guanine NCE adducts in comparison were more
stable. The addition of high ascorbic acid concentrations (2 mM)
has been suggested to protect metabolites from oxidative
degradation [23]. Stabilization of NCE adducts by citric acid
and EGTA as metal ion chelators was also explored in cell culture
media using the synthetic adduct standards and LC-MS/MS
analysis. The highest recovery of adducts was obtained using citric
acid and ascorbic acid (both 2 mM) added to the media before
extraction (Figure S3).
Attenuation of NCE adduct formation by DMA
Regular administration of E2 with fresh media twice weekly in
MCF-10A cells, and analysis of collected media (after 3 or 4 days
of treatment) showed significantly increased levels of NCE
adducts. Both 4-OHE2 and 4-OHE1 guanine adducts were
detected (Figure 6A, 6B) and a representative measurement of 4-
OHE2 guanine adducts is shown in Figure 6C. Levels of NCE
adducts measured in media from cells treated with E2 were
Figure 3. Induction of CYP450 1B1 expression in MCF-10A cells
by E2 (1 mM). Cells were collected at different time points (24 h, 2, 3
and 6 days). Increased CYP450 1B1 mRNA levels A. from E2 treatment
measured with real-time PCR, correlate with protein levels B. extracted
and analyzed by western blot using anti CYP450 1B1 rabbit polyclonal
primary antibody. Representative blots are shown of the 55 kDa
immunoreactive band. Intensity of the bands was normalized to b-actin
(N=6) showing mean and s.e.m.
doi:10.1371/journal.pone.0027876.g003
Figure 4. Malignant transformation induced by endogenous
estrogens is inhibited by benzothiophene SERMs, but not by
HDAC inhibitors. MCF-10A cellular transformation induced by E1 or E2
in the presence of benzothiophene SERMs (1 mM) was measured as
anchorage-independent growth in soft agar after four weeks. A. DMA
or B. DMA and the structurally related SERM, raloxifene. Cells were
treated for four weeks before transfer to soft agar. Using one-way
ANOVA with Dunnett’s post test: *** p,0.001 versus DMSO control.
doi:10.1371/journal.pone.0027876.g004
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6B).
NCE adduct formation from the nucleotide pool
Cellular concentrations of nucleotides have been measured at
millimolar levels [24]. Guanosine and adenosine nucleotides play
essential roles in cell function and the deoxynucleotide pool
(dNTP) also provides potential substrates for NCE adduction,
however, adduction of the free cellular nucleotide pools has not
been previously considered as a source of the NCE adducts
reported from cell culture media and human samples. The o-
quinone of 4-OHE2 was freshly prepared by oxidation with MnO2
as previously described [25], followed by incubation with Gua and
Ade nucleotides at pH 3.7 or pH 6.8. At both pHs, formation of
the NCE-Gua adduct was observed from the reaction of quinone
with nucleotide and subsequent depurination over the course of
24 h (Figure 7A, 7B). At pH 6.8, the amount of 4-OHE2-1-
N7Gua generated from different nucleotides at 24 h, followed the
order: dGTP.dGDP.dGMP.GTP.GDP. Since reaction of
quinone with guanine is expected to be rapid, the pseudo-first
order kinetics of NCE-Gua formation observed, with half-lives of
,2–3 h, likely reflects the slower rate of depurination (Figure 7A).
The depurination of NCE-adenosine nucleotide adducts was not
observed from ADP and dAMP under the same conditions. The
reaction of catechol estrogen quinone with the nucleotide pool and
depurination to give NCE-Gua adducts is feasible under
physiological conditions, at least for Gua-nucleotides and repre-
sent a source of such adducts in cell cultures and human samples.
DNA oxidation in response to catechol estrogen
treatment
Surh et al. reported a fourfold increase in 8-oxo-dG levels after
treatment of MCF-10A cells with 4-OHE2 for 6 h [26]. Herein, 8-
oxo-dG was measured in DNA isolated from MCF-10A cells at a
similar time point to NCE adduct measurements (3 days). In order
to analytically detect 8-oxo-dG, MCF-10A cell were treated with
4-OHE2 (1 mM) alone or with co-administration of DMA (1 mM)
for 72 h: 4-OHE2 induced formation of 8-oxo-dG, which was
ablated by co-treatment with DMA (Figure 8).
Discussion
Lifetime exposure to estrogens is a recognized contributor to
breast cancer development [27]. Oxidative metabolism of
estrogens by hydroxylation to form catechol estrogens and further
oxidation to electrophilic and redox-active quinones is equally
recognized to provide a potential chemical carcinogenesis
contribution to mutagenesis, cancer initiation, and promotion
(Figure 1) [28]. While enzyme-dependent hydroxylation is the
necessary first step, cellular electrophilic and oxidative stress is
dependent on rates of quinone formation and reaction, nuclear
availability, cellular redox state, and detoxification by phase II
enzymes. In the hamster kidney tumor model, the catechol
estrogens, 4-OHE1 and 4-OHE2 were observed to be carcinogen-
ic, whereas the corresponding 2-OH-isomers were not [29,30]. In
human and animal tissues susceptible to estrogen-induced tumors,
the elevated expression of estrogen-4-hydroxylase activity is seen
as support for a role for the 4-OH-catechol pathway in
tumorigenesis [31,32]. It has been reported previously that
MCF-10A and MCF-10F cells undergo estrogen-induced malig-
nant transformation, as shown by formation of anchorage-
independent colonies in soft-agar media, considered a character-
istic of malignant transformation [33,34]. Since MCF-10A and
10F cells do not respond to the proliferative, hormonal actions of
estrogens, these non-tumorigenic, human, mammary, epithelial
cells are often classified as ER-negative and represent a model for
studying estrogen-induced chemical carcinogenesis in the absence
of dominant hormonal contributions. In accord with previous
work, transformation of MCF-10A cells was induced by treatment
with E1,E 2, 4-OHE2, and 4-OHE1; whereas, the non-carcino-
genic 2-OHE1 did not induce malignant transformation.
The catechol equine estrogen, 4-OHEN, is the major oxidative
metabolite of the equine estrogens, equilenin and equilin, that
constitute 50% of the widely prescribed ERT formulation,
Premarin [35]. The equine estrogens, in contrast to B-ring
saturated estrogens, are predominantly oxidatively hydroxylated at
the 4-position, and furthermore 4-OHEN readily autoxidizes to an
o-quinone that reacts with DNA leading to a variety of DNA
lesions [36,37,38]. In human breast cancer cells, 4-OHEN was
observed to induce DNA damage and apoptosis [39], and was
toxic towards MCF-10A cells in the presence of COMT inhibitor.
At lower concentrations, 4-OHEN induced malignant transfor-
mation, although colony growth was below that observed for 4-
OHE2; induction by EN itself did not reach significance. It is
tempting to link the observation of reduced transformation by
equine estrogens with epidemiological data suggesting that ERT
formulations based on equine estrogens are in fact safer, however,
further studies are needed [40].
Two separate hypotheses have been proposed for estrogen-
induced transformation of MCF-10A and MCF-10F cells.
Anchorage-independent growth of MCF-10A cells induced by
high concentrations of E2 (20 mM) was linked to CYP450 1B1
mediated oxidative metabolism, generation of ROS as a
consequence of 4-OHE2 oxidation, and activation of NFkB [33].
Although elevation of ROS in the nucleus leading to DNA
oxidation is a known potential, mutagenic pathway [33,41], NFkB
activation was argued to be causal [42]. In the present work,
CYP450 1B1 was observed to be upregulated in MCF-10A cells
on treatment with E2 and co-treatment with a CYP450 inhibitor
completely attenuated malignant transformation in response to E1.
Figure 5. Biomarker study of guanine NCE adducts measured
in supernatant of cells treated with E2 and catechol metabo-
lites; guanine adducts correlate with transformation potency.
Guanine NCE adducts of 4-OHE1 were measured in media from MCF-
10A cells treated with: E2 1 mM, 4-OHE2 1 mM, or (4-OHE2 1 mM+Ro
3 mM) at week 4. These NCEs adducts were not detectable in vehicle
control experiments. N7-Me-guanine (5 nM) was used as internal
standard. MRM fragmentation patterns of NCEs (m/zRm/z) corre-
sponded to: Gua NCE Adduct 1 4-OHE1-Gua (436R152); Gua NCE Adduct
2 4-OHE2-Gua adduct (438R152).
doi:10.1371/journal.pone.0027876.g005
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DMA. Cell culture supernatant was analyzed after 4 days of treatment and 1 week post cell-plating. LC-MS/MS peak area for A. 4-OHE2-1-N7Gua and
B. 4-OHE1-1-N7Gua was normalized to equal amounts of internal standard
15N-labeled Gua adduct. C. Representative chromatograms of guanine NCE
adducts obtained with the TSQ MS instrument. Guanine adduct 4-OHE2-1-N7Gua from MCF-10A cell media treated with 1 mME 2 after 3 days.
15N-
labeled guanine adduct shown in red is the internal standard.
doi:10.1371/journal.pone.0027876.g006
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suggests that transformation results from induction of cellular
oxidative or electrophilic stress by the 4-OH catechol estrogen.
Elevated levels of 8-oxo-dG were also observed, confirming
induction of oxidative stress leading to DNA oxidation.
The second hypothesis posits DNA damage via formation of
NCE adducts as causal in malignant transformation, the
foundation being comparison of levels of NCE adducts to stable
DNA adducts after reaction of estrogen quinones with DNA [43].
Stable adducts detected by P
32-postlabeling analysis were reported
to be 10–50 fold more abundant from reaction with 2-OH
estrogen catechol quinones, incompatible with the lower carcino-
genicity of 2-OHE2 versus 4-OHE2 [17,44,45]. The predominant
formation of NCE adducts from 4-OH estrogens was interpreted
as evidence for a causal role for 4-OHE-NCE adducts in
carcinogenesis [46]. Furthermore, 4-OHE-1-N7Gua NCE adducts
were detected from female Sprague-Dawley rats treated with 4-
OHE2 at levels orders of magnitude greater than stable adducts
detected by P
32-post-labeling [47], underpinning the theory of
formation of abasic sites by depurination of DNA as the cause of
estrogen-induced mutagenesis [23,48,49,50]. However, abasic sites
are a natural intermediate in base excision repair and are present
at very high levels in normal cells [51]. In the present work, 4-
OHE-1-N7Gua was measurable by LC-MS/MS analysis of
Figure 7. Formation of 4-OHE2-1-N7Gua from reaction of E2-3,4-Q with free Gua nucleotides. A. Reaction of quinone (0.2 mM) with
dGMP (red), dGDP (blue), or dGTP (green) (1.9 mM) buffered at pH 6.8 (phosphate, 10 mM). Data are fit to a pseudo-first order exponential.
B. Representative chromatogram of 4-OHE2-1-N7Gua.
doi:10.1371/journal.pone.0027876.g007
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4-OHE2 with and without COMT inhibitor. However, production
of 4-OHE2-1-N7Gua was observed from the reaction of the
estrogen 3,4-o-quinone with dGTP, dGDP, dGMP, GTP, and
GDP, with the highest yield from dGTP. The generation of o-
quinones from CYP450-mediated metabolism of estrogens, in the
presence of cellular nucleotide pools that may be at millimolar
levels, raises the possibility that these may be the source of NCE
adducts. Indeed, adduction of dNTP and incorporation into DNA
has been considered as a mutagenic mechanism [52]. Therefore,
the alternative hypothesis must be considered that 4-OHE2-1-
N7Gua represents a quantitative biomarker of cellular electro-
philic stress from the free nucleotide pool.
Estrogen-induced malignant transformation of MCF-10A cells,
measured by anchorage-independent growth, was inhibited by the
SERMs raloxifene and DMA. In addition to potential clinical
relevance, this observation allowed testing of the correlation of
biomarkers of oxidative and electrophilic stress with attenuated
transformation. Prevention by DMA was shown to be accompa-
nied by significant attenuation of NCE adduct formation and also
by blockade of estrogen-induced 8-oxo-dG formation.
The detailed mechanism by which raloxifene and DMA
attenuate malignant transformation requires further study. Clas-
sical ER-dependent mechanisms are unlikely to be effective, since
the antiestrogen ICI 182780 was previously shown to be ineffective
in inhibition of the transformation phenotypes induced by E2 and
4-OHE2 [44]. The phenolic antioxidant resveratrol has been
reported in MCF-10 cells to inhibit estrogen-induced malignant
transformation [34,53,54]. Furthermore, a quinone-forming
catechol metabolite of resveratrol, was reported to inhibit
estrogen-induced malignant transformation in MCF-10A cells by
reaction of the quinone with essential cysteine residues in IKK
kinases [64]. Both raloxifene and DMA are phenolic antioxidants;
are oxidatively activated to quinones that have been shown to
modify protein-cysteine residues; and, have demonstrated ER-
independent chemopreventive activity [19,55,56,57].
Conclusions
This is the first report that the benzothiophene SERMs,
raloxifene and DMA, block estrogen-induced malignant transfor-
mation of human breast epithelial cells. This observation and that
of lower transformation by equine estrogen components of ERT
may of clinical relevance. Attenuated cellular transformation by
DMA allowed correlation with biomarkers of cellular oxidative
and electrophilic stress, 8-oxo-dG and NCE adducts, respectively.
CYP450 oxidative metabolism of estrogens is required to induce
malignant transformation that is accompanied by oxidative and
electrophilic stress, and the formation of NCE adducts may occur
from reaction of quinones with free nucleotide pools, which has
not previously been considered.
Materials and Methods
Materials and Reagents
E1/E2, EN, 4-OHE1/E2, 2-OHE1 estrogens were obtained
from Steraloids Inc. (Newport, RI). aNF, Ro 41-0960 (Ro),
solvents, reagents and other synthesis chemicals were obtained
from Sigma (St. Louis, MO). SAHA and TSA were obtained from
Cayman Chemical (Ann Arbor, MI). DMA was synthesized as
described previously [58]. 4-OHEN was synthesized by treating
equilin (EQ) with Fremy’s salt as described previously [32] with
minor modifications [37].
Cell Culture
All cell culture reagents were purchased from Invitrogen
(Carlsbad, CA) unless stated otherwise. MCF-10A cells were a
kind gift from Dr. Meiling Chen (UIC), originally from MCF.
MCF-10A cells are grown in phenol red free (PRF) D-MEM/F-12
media supplemented with 100 ng/mL cholera toxin, 10 g/mL
insulin, 0.5 g/mL hydrocortisol, 20 ng/mL EGF, 1% 10,000 U
penicillin G, 10 mg/mL streptomycin, and 5% stripped FBS.
Estrogen-free media was prepared by supplementing 36dextran-
coated charcoal-treated FBS. MCF-10A cells were treated with
each compound (1 mmol) twice weekly for four weeks. Cells were
passaged weekly or as needed throughout the four-week treatment.
For DNA oxidation experiments, MCF-10A cells were plated in
15 cm-dishes at 2610
6 cells density. Cells were allowed to attach
overnight and then were treated with 4-OHE2 with DMA for
72 h.
Sample Preparation
For solid phase extraction of NCE adducts, media was collected
every 3 or 4 days at which time ascorbic acid (AA) 2 mM and
citric acid (CA) 2 mM were added to minimize oxidative
degradation of NCE adducts in the media based on preliminary
stability studies. Media was analyzed immediately or stored at
220uC. In order to analyze the media for formation of
depurinating adducts, ice-cold acetone was added to induce
protein precipitation and possible dissociation of the lipophilic
depurinating adducts from media proteins. Before further
manipulation, known amounts of stable isotopically
15N-labeled
internal standards of adenine and guanine adducts were added
into the media. The media and acetone mixture was stored at
220uC for 30 min and centrifuged at 10 K for 15 min. Acetone
was removed from supernatant by nitrogen bubbling. NCE
adducts were extracted by a C8 gravity column (Bond Elut,
Varian), followed by elution with MeOH/H2O/TFA (8:1:0.1), or
ACN/MeOH/H2O/FA (8:1:1:0.1). After drying, samples were
dissolved in MeOH.
DNA extraction for 8-oxo-dG analysis was run as previously
described [59] with minor modifications. The cells were washed
with ice-cold PBS (10 mM, pH 7.4) and collected by scraping in
4 mL PBS final volume. The collected cells were centrifuged at
1,500 rpm for 5 min. After centrifugation, the cell pellets were
Figure 8. 4-OHE2 induced oxidative damage in MCF-10A cells
and DMA prevents the formation of 8-oxo-dG. Cells were treated
with 1 mM 4-OHE2 with or without DMA 1 mM for 72 h. 8-Oxo-dG was
detected and quantified by LC-MS/MS and dG was measured by HPLC.
Data show mean and s.e.m. p,0.05 versus vehicle control and DMA co-
treated group by ANOVA with Tukey’s post test.
doi:10.1371/journal.pone.0027876.g008
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Tris, pH 7.4, 5 mM MgCl2, 10 mM Triton X-100, and 50 mM
mannitol). The nuclei pellets were treated for 30 min at 37uC with
RNase T1 (1000 units) and RNase A (0.2 mg, 2 units) in 997 mL
solution buffer (1% SDS, 1 mM EDTA, 10 mM Tris, pH 7.4,
0.45 M NaCl) and further incubated with proteinase K (0.8 mg)
for 30 min at 37uC. After cooling down the samples at 4uC, NaCl
(5 M, 171 mL) and Tris (1 M, 14.2 mL, pH 7.4) were added to
achieve final concentration of 0.62 M and 20 mM, respectively.
After 1 mL of chloroform/isoamyl alcohol mixture (24:1, v/v) was
added, the samples were thoroughly mixed by vortex for 20 sec
and centrifuged at 4,000 rpm for 15 min, followed by isolation of
the upper aqueous layer. Then an equal volume 1:1 (v/v) of ice-
cold isopropanol was added, gently mixed by inverting and kept at
220uC for 30 min for DNA precipitation. The DNA was washed
three times with 70% ethanol. Finally, DNA was isolated in
100 mL of 25 mM ammonium acetate buffer (pH 6.8) containing
1 mM ZnCl2 and 10 mM MgCl2. The DNA concentrations were
calculated by measuring the absorbance at 260 nm according to
the ratio of one absorbance units equals 50 mg/mL of DNA. DNA
hydrolysis was carried out in DNA solution mixed with 1 mLo f
10 mM deferoxamine and 0.5 mL of 10 mM BHT, and
hydrolyzed by incubation with DNase 1 (20 units, in a reaction
buffer containing Tris, pH 7.4, 1 mM MgCl2) and nuclease P1 (10
units) at 55uC for 3 h. The mixture was further incubated with
alkaline phosphatase from calf intestine (15 units), phosphodies-
terase I (1 unit, in a reaction buffer containing 10 mM Tris, pH 8)
and 5 mL of MgCl2 (10 mM) at 37uC for 3 h. After incubation,
10 mL of ammonium acetate (0.1 M, pH 5.3) was added to
neutralize solution. Stable isotopically labeled
15N58-oxo-dG was
added to the solution as internal standard. The mixtures were then
centrifuged for 15 min at 13,000 r.c.f. using Costar 0.22 mm nylon
filters.
MS Instrumentation and HPLC
The NCE LC/MS/MS analysis was completed by either of two
methods. (1) An Agilent API-3000 (Applied Biosystems) triple-
stage quadrupole mass spectrometer utilizing the electrospray
ionization method coupled to a Shimadzu LC-1-AD HPLC system
and utilizing the electrospray ionization method. Adducts were
resolved by HPLC on a Waters X-Bridge C18 column (3.5 mm;
2.1 mm6150 mm) at a flow rate of 0.2 mL/min with a 5 min
linear gradient of A (acetonitrile, ACN and 0.1% formic acid, FA)
and B (H2O and 0.1% FA) from 10% to 60%, then 60% to 90% in
8 min, and then holding constant 90% A for an additional 3 min.
The column was returned to original conditions in 2 min, and
allowed to equilibrate for another 8 min under initial conditions.
(2) A TSQ quantum triple quadrupole mass spectrometer
(Thermo Finnigan) instrument coupled to HPLC, while adducts
were resolved with an X-Bridge phenyl column (3.5 mm;
2.1 mm6150 mm) at a flow rate of 0.2 mL/min with a 4 min
linear gradient of A (ACN) and B (H2O and 0.1% FA) from 20%
to 60%, then 60% to 85% in 7 min, then 85% to 90% in 1 min,
and then holding constant 90% A for an additional 3 min. The
column was returned to original conditions in 3 min. Adducts
were confirmed against N
15-labelled guanine and adenine adducts.
The collision energies were optimized at 55 volts for guanine
adducts and 53 volts for adenine adducts. Samples were detected
using ESI positive MRM mode carried out at 350uC. In the TSQ
instrument, collision energies were optimized to 47 and 50 volts for
E1 and E2 adenine adducts respectively, and 49 and 50 volts for E1
and E2 guanine adducts respectively.
The 8-oxo-dG LC/MS/MS method was completed on API
3000 (Applied Biosystem, Foster City, CA, USA) triple quardru-
pole mass spectrometer attached to Agilent 1200 HPLC (Agilent
Technologies, Santa Clara, CA). First, stable isotopically labeled
15N58-oxo-dG was added to the solution as internal standard. The
samples were separated using a Phenomenex Kinetex C18 column
(36100 mm, 2.6 mm) and ADV-FFKIT filter (Analytical, Promp-
ton Plains, NJ, USA) at a flow rate of 0.3 mL/min with a gradient
mobile phase starting 10% methanol for 1 min, and increasing to
40% methanol over 4 min, increasing to 50% methanol over
3 min, increasing to 60% methanol over 5.5 min, keeping to 60%
for 1.5 min and then equilibrium with 10% methanol for 9 min.
The native dG was determined by HPLC (UV) scanning from
280 nm. The 8-oxo-dG was detected multiple reaction monitoring
and collision-induced dissociation for the fragmentation pathway
of m/z 284R168 and m/z 289R173 for
15N58-oxo-dG using
positive ion electrospray.
Synthesis of Standards
For NCE standards, E-3,4-Q was prepared by MnO2 catalyzed
oxidation in CHCl3 as described previously with minor modifi-
cations [25]. To a solution containing 4-OHE1 (8 mg, 0.028 mM)
in dry CHCl3 (1.5 mL) at 230uC was added activated MnO2
(25 mg). The reaction was stirred for 10 min and the solution was
filtered. The resulting solution was evaporated in nitrogen
atmosphere at 230uC. The resulting brown solid was dissolved
in an equal volume of DMF or acetonitrile. Reaction of E-3,4-Q
with deoxyguanosine (dG) and deoxyadenosine (dA): the synthesis
was carried out as reported previously [60]. Briefly, to a solution
containing 29-deoxyguanosine (30 mg, 0.112 mM) or 29-deoxya-
denosine (30 mg, 0.119 mM) in 1 mL of acetic acid/water (50/50,
v/v) was added E-3,4-Q (8 mg, 0.028 mM) and the mixture was
stirred at room temperature for 4 hours. The reaction mixture was
filtered and the nucleic acid adduct of E1 was purified by reverse
phase HPLC (20 mm6250 mm, 100 A ˚ C18 column; flow rate
5.0 mL/min, mobile phase 5% to 90% acetonitrile gradient in
water over 25 min, held at 90% for 15 min.) Guanine adduct 4-
OHE1-1-N7Gua (3 mg, 0.007 mM) was obtained as a solid and
E1-adenine adduct was not formed in this reaction. Above
procedure was followed to synthesize
15N5-guanine adduct.
Reaction of E-3,4-Q with adenine: the synthesis was carried out
as reported previously [61,62,63]. To a reaction mixture in DMF
containing sodium dithionite (15 mg, 0.086 mM) and adenine
nucleic acid base (0.22 mM) was added E-3,4-Q (8 mg,
0.028 mM) and the mixture was stirred at room temperature
under nitrogen for 45 min. The reaction mixture was filtered and
evaporated DMF in vacuo. The adenine nuclear base adduct-E1
was purified by reverse phase HPLC (20 mm6250 mm, 100 A ˚
C18 column; flow rate 5.0 mL/min, mobile phase 5% to 90%
acetonitrile gradient in water over 25 min, held at 90% for
15 min.) Adenine adduct 4-OHE1-1-N3Ade was isolated. Above
procedure was also followed to synthesized
15N2-adenine adduct.
For 8-oxo-dG standard, stable isotopically labeled
15N5-8-oxo-dG
was synthesized as described previously [64].
Kinetic study of NCE adduct formation from free
nucleotide pool
All stock solutions of nucleotides (dGMP, dGDP, dGTP, GTP,
GDP, dAMP, ADP) were prepared freshly before the initiation of
the reaction in either pH 6.8 10 mM phosphate buffer or pH 3.7
10 mM citric buffer. The stock solution of E2-3,4-Q (ca. 4 mM)
was made in a mixture of ACN/DMF (3/1 v/v) and stored at
220uC. The reaction was initiated by mixing 25 mL stock solution
of E2-3,4-Q with 475 mL of 2 mM nucleotide solution in buffer
that was pre-incubated at 37uC for 10 min. The initial
concentrations of E2-3,4-Q and nucleotide in the reaction mixture
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mixture was kept at 37uC and monitored by HPLC (Shimadzu)
with UV detection at 254 nm and 280 nm for 24 hrs. The
formation of 4-OHE2-1-N7Gua was confirmed by comparing with
the synthetic standard using HPLC and LC-MS/MS (Agilent, Ion-
trap). The kinetics of the formation of E2-guanine adduct was
studied by measuring the changes in the HPLC peak area of 4-
OHE2-1-N7Gua as a function of time. The LC condition used for
both HPLC and LC-MS/MS is as follows: Analytical Advantage
ARMOR C18 column, (5 mm, 4.6 mm6150 mm), flow rate
1.0 mL/min, the elution program started with 30% of B (MeOH)
for 5 min then gradient to 98% in A (H2O with 10% of MeOH)
over 20 min, held at 98% of B for 8 min, returned to 30% of B in
5 min and held for an additional 2 min.
Anchorage Independent Growth in Soft Agar
After the 4-week treatment, cells were seeded at 50,000 cells/
well density in triplicates in 12-well plates. Cells were suspended in
1 mL of 0.35% soft agar in media, over 1.5 mL of 0.7% soft agar.
Colonies of transformed cells were allowed to grow for another
four weeks at 37uC and 5% CO2. Anchorage-independent growth
(spherical formation of $10 cells) was scored using a light
microscope, by counting foci in 0.25 mm
2 areas [65].
Western Blots and PCR
MCF-10A cells were treated with E2, EN, and E2+DMA,
1 mmol each for various incubation times as indicated. Cells were
trypsinized, pelleted, washed in PBS, resuspended in IP buffer
(50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 2.5 mM EGTA,
10 mM b-glycerophosphate, 10% glycerol, and 0.5% NP-40,
pH=8.0) containing protease inhibitors, mixed, and centrifuged at
12,000 g for 10 min. Protein concentration was measured in
supernatants using the Bradford assay kit (Bio-Rad Laboratories).
Equal aliquots of total protein samples (20 mg per lane) were
electrophoresed on a 4–12% Bis-Tris polyacrylamide gel,
transferred to PVDF membranes (Millipore, Bedford, MA), and
blotted using antibodies to CYP450 P450 1B1 from Santa Cruz
Biotechnology (Santa Cruz, CA). b-actin antibody was from Cell
Signaling Technology (Beverly, MA); it was used as a control for
loading and transfer. The blotted proteins were visualized using
the enhanced chemiluminescence detection system from Amer-
sham Biosciences (Piscataway, NJ) and quantitated using DT
software.
For PCR, MCF-10A cells were plated in 100 mm dishes and
treated with vehicle control DMSO, E2 1 mmol for various
incubation times as indicated. mRNA was collected according to
standard Trizol method (manufacture’s protocol, Invitrogen).
For quantitative PCR (experiment run in Jonna Frasor’s Lab,
UIC), the primers used for CYP450 P450 1B1 were forward
59 CATGAGTGCCGTGTGTTTCG and reverse 59 TCTT-
CGTTGTTGGCTGAGCAG. One mg of total RNA was
reverse transcribed using Moloney murine leukemia virus
reverse transcriptase. The resulting product was diluted to
200 mL with double-distilled H2O, and 2 mL were used for each
subsequent QPCR. QPCR was carried out and analyzed as
previously described [66].
Statistics
The data were reported as the mean 6 S.E.M. One-way
ANOVA analysis with Tukey’s multiple comparison test was done
using Graph-Pad Prism version 4.00 for Windows, GraphPad
Software.
Supporting Information
Figure S1 Malignant transformation induced by endog-
enous estrogens is not inhibited by cotreatment with
HDAC inhibitors. MCF-10A cellular transformation induced
by E2 1 mM in the presence of HDAC inhibitors, suberoylanilide
hydroxamic acid (SAHA) and trichostatin A (TSA) tested at
100 nM each. Cells were treated for four weeks before transfer to
soft agar. Using one-way ANOVA with Dunnett’s post test:
*** p,0.001 versus DMSO control.
(TIF)
Figure S2 Stability of depurinating adducts at various
pHs incubated for 4, 16 and 27 h. Known concentrations of
4-OHE1-1-N3Ade in A. and 4-OHE1-1-N7Gua in B. were
incubated in PBS buffer at different pHs. Data shown represent
the MS signal normalized to the universal highest signal detected
in the study for each adduct.
(TIF)
Figure S3 Stability and proper storage of depurinating
adducts. A. Stability of 4-OHE1-1-N3Ade incubated in cellular
media at 37uC for 24 h and extracted after the addition of AA
2 mM alone or together with 2 mM EGTA and CA 2 mM.
B. Stability of 4-OHE1-1-N7Gua measured by the API triple
quadrupole MS by quantifying the peak height (PH). C. Similar
results were obtained by measuring the 4-OHE1-1-N7Gua, in the
TS quantum MS by quantifying the peak area (PA). The presence
of both AA and CA increased the amount depurinating adducts
recovered. All data is normalized to equimolar internal standard
15N-labeled 4-OHE1-1-N7Gua.
(TIF)
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